Comprehensive characterization of evolving immune checkpoint inhibitor (ICI) indications and outcomes
Our joint poster with UZA, az groeninge, UZ Brussel and AZ Maria Middelares dives into real-world ICI use across more than 20 cancer types. In our study, we applied the OMOP Common Data Model (CDM) to enable standardized, cross-domain analyses of ICI treatment patterns that can be visualized in a user-friendly dashboard.
Our joint poster covers:
▪️A granular characterization of real-world ICI usage and outcomes
▪️An interactive dashboard for subgroup exploration
▪️A newly developed classifier for tumor staging using fragmented TNM values
Our joint poster covers:
▪️A granular characterization of real-world ICI usage and outcomes
▪️An interactive dashboard for subgroup exploration
▪️A newly developed classifier for tumor staging using fragmented TNM values
